Consensus Statement on the Outcome of the European Herbal Health Products Summit – Which Way Forward?
Planta Medica · 01.11.2024 · 90 (14) · 1052-1055
DOI: 10.1055/a-2419-1602 ↗Kurz gefasst
Fachartikel in der Zeitschrift Planta Medica, erschienen am 01.11.2024. Verfasst von Michael Heinrich und 5 weiteren Autor:innen. Beteiligte Einrichtung: Society of Medicinal Plants and Natural Product Research (GA), Neumarkt, Germany. Hauptthemen laut MEDLINE: Plants, Medicinal. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Herbal medicinal products are a vital part of the healthcare system in Europe and beyond. Being predominantly sold as non-prescription medicines in pharmacies, they are very popular with patients, physicians, and pharmacists and are therefore an important part of self-medication. Interest in this sector has recently gained momentum, reflecting the ongoing revision of the general pharmaceutical legislation and the recent discussion on nutrition and health claims on foods based on the implementation report of Regulation (EC) No 1924/2006 by the European Parliament 1. Therefore, on 20th February 2024, the Society for Medicinal Plant and Natural Product Research (GA), in collaboration with the German Pharmaceutical Industry Association (BPI) and the German Medicines Manufacturersʼ Association (BAH, now Pharma Deutschland), hosted an in-person summit in Brussels entitled ‘European Herbal Health Products Summit – Which way forward?ʼ. The summit featured a wide range of speakers, including policymakers, regulatory authorities, industry representatives, and academic experts. It was divided into several sessions covering topics such as the future and relevance of herbal medicinal products in the EU, the revision of the EU pharmaceutical legislation, and the resulting impact on herbal medicinal products. Furthermore, the discussions delved into the “Health Claims Regulation” – the European Parliamentʼs implementation report and the related regulatory challenges of herbal medicinal products at an EU level. This consensus paper summarises the current status and provided recommendations to pave the way for future strategies to ascertain the continued use of herbal medicinal products as an important therapeutic option for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Society of Medicinal Plants and Natural Product Research (GA), Neumarkt, Germany.
- Pharmacognosy & Phytotherapy, UCL School of Pharmacy, London, United Kingdom/Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Chinese Medicine, China Medical University, Taichung…
- G. Pohl-Boskamp GmbH & Co.KG, Hohenlockstedt, Germany.
- Bionorica SE, Neumarkt, Germany.
- Dr. Willmar Schwabe GmbH & Co.KG, Karlsruhe, Germany.
- Bundesverband der Pharmazeutischen Industrie e. V., Berlin, Germany.
ORCID-Profile: Michael Heinrich
Zitieren
APA
Heinrich, M., Reiken, B., Roether, B., Müller, A., Rumsch, J., & Symma, N. (2024). Consensus Statement on the Outcome of the European Herbal Health Products Summit – Which Way Forward?. Planta Medica, 90(14), 1052-1055. https://doi.org/10.1055/a-2419-1602
Vancouver
Heinrich M, Reiken B, Roether B, Müller A, Rumsch J, Symma N. Consensus Statement on the Outcome of the European Herbal Health Products Summit – Which Way Forward?. Planta Medica. 2024;90(14):1052-1055. doi:10.1055/a-2419-1602
BibTeX
@article{Heinrich2024,
author = {Heinrich, Michael and Reiken, Babette and Roether, Bernd and Müller, Angela and Rumsch, Julia and Symma, Nico},
title = {Consensus Statement on the Outcome of the European Herbal Health Products Summit – Which Way Forward?},
journal = {Planta Medica},
year = {2024},
volume = {90},
number = {14},
pages = {1052--1055},
doi = {10.1055/a-2419-1602}
}
EUVIMED